EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas.

Autor: Maracaja DLV; Departments of Pathology and Laboratory Medicine., Puthenpura V; Section of Pediatric Hematology/Oncology, Department of Pediatrics, Yale School of Medicine, New Haven, CT., Pels SG; Section of Pediatric Hematology/Oncology, Department of Pediatrics, Yale School of Medicine, New Haven, CT., O'Malley DP; NeoGenomics, Aliso Viejo, CA., Sklar JL; Departments of Pathology and Laboratory Medicine., Finberg KE; Pathology., Xu ML; Departments of Pathology and Laboratory Medicine.

Publikováno v: Applied immunohistochemistry & molecular morphology : AIMM [Appl Immunohistochem Mol Morphol] 2020 Nov/Dec; Vol. 28 (10), pp. 725-730.

Novel--and Not So Novel--Inhibitors of the Multifunctional CRM1 Protein.

Autor: Aumann, Waitman K.^1,2 waitman.aumann@emory.edu, Kazi, Rafi³, Harrington, Amanda M.⁴, Wechsler, Daniel S.^1,2

Publikováno v: Oncology Reviews. 2024, p1-19. 19p.

Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes.

Autor: Cecchini M; Department of Medicine, Medical Oncology, Yale School of Medicine, New Haven, CT, USA., Walther Z; Department of Pathology, Yale School of Medicine, New Haven, CT, USA., Sklar JL; Department of Pathology, Yale School of Medicine, New Haven, CT, USA., Bindra RS; Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, USA., Petrylak DP; Department of Medicine, Medical Oncology, Yale School of Medicine, New Haven, CT, USA., Eder JP; Department of Medicine, Medical Oncology, Yale School of Medicine, New Haven, CT, USA., Goldberg SB; Department of Medicine, Medical Oncology, Yale School of Medicine, New Haven, CT, USA. Electronic address: sarah.goldberg@yale.edu.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2018 Jan; Vol. 19 (1), pp. 23-24.

Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial.

Autor: Lih CJ; Molecular Characterization and Clinical Assay Development Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Harrington RD; Molecular Characterization and Clinical Assay Development Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Sims DJ; Molecular Characterization and Clinical Assay Development Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Harper KN; Molecular Characterization and Clinical Assay Development Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Bouk CH; Molecular Characterization and Clinical Assay Development Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Datta V; Molecular Characterization and Clinical Assay Development Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Yau J; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Singh RR; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Routbort MJ; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Luthra R; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Patel KP; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Mantha GS; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Krishnamurthy S; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ronski K; Department of Pathology, School of Medicine, Yale University, New Haven, Connecticut., Walther Z; Department of Pathology, School of Medicine, Yale University, New Haven, Connecticut., Finberg KE; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Canosa S; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Robinson H; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts., Raymond A; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts., Le LP; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts., McShane LM; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Polley EC; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Conley BA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Iafrate AJ; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts., Sklar JL; Department of Pathology, School of Medicine, Yale University, New Haven, Connecticut., Hamilton SR; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Williams PM; Molecular Characterization and Clinical Assay Development Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland. Electronic address: mickey.williams@nih.gov.

Publikováno v: The Journal of molecular diagnostics : JMD [J Mol Diagn] 2017 Mar; Vol. 19 (2), pp. 313-327. Date of Electronic Publication: 2017 Feb 07.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.